Autopsy report · NCT00905398
Nilotinib With Chemotherapy for the Treatment of Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
Cause of deathSlow enrollment, also safety
“The study was terminated due to excessive toxicity and low compliance to the protocol scheme.”
Life of this trial
- Ran for about 6 years 2 months before it stopped.
- 8 participants enrolled.
- No results are posted on the registry.
Vital statistics
- Status
- Terminated
- Phase
- Phase 1, Phase 2
- Sponsor
- Rony Schaffel
- Sponsor type
- University, hospital or other
- Conditions
- Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Acute Lymphoblastic Leukemia
- Interventions
- Nilotinib
- Participants
- 8
Trials that died the same way
- A Dose Exploration Study With Birabresib (MK-8628) in Participants With Selected Hematologic Malignancies (MK-8628-005)
“This study was terminated due to limited efficacy and not due to safety reasons” - An Efficacy and Safety Study of Golimumab in Participants With Ulcerative Colitis
“Protocol was cancelled by company based on overall efficacy, no safety concern” - Improving Medication Adherence in Post-ACS Patients
“This was a dosing study to determine acceptability. Participants found protocol burdensome and so we terminated.” - A Study of THE-630 in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)
“The Sponsor terminated the study due to early dose-limiting toxicities.” - Relative Bioavailability Study of Ropinirole Implants in Parkinson's Patients on L-Dopa Switched From Oral Ropinirole
“This study was terminated for reasons not related to efficacy or safety”
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.